Search clinical trials for: Refractory colorectal cancer

Total 91710 results

Sun Yat-sen University

Recruiting

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Colorectal Cancer

China
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer (NOTABLE-308)

Refractory Metastatic Colorectal Cancer
GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Fudan University

Recruiting

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Carcinoma

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Wuhan Union Hospital, China

Recruiting

Fruquintinib in the Cross-line Treatment of Refractory mCRC

Metastatic Colorectal Cancer | Fruquintinib

China
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens

Liver Metastasis Colon Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Metastatic Colorectal Cancer

China
Holy Stone Healthcare Co., Ltd

Not yet recruiting

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Charite University, Berlin, Germany

Recruiting

Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer (Live-RF)

Refractory Metastatic Colorectal Cancer

Germany
Qurgen Inc.

Recruiting

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor

United States
Orion Biotechnology Polska Sp. z o.o.

Not yet recruiting

Study of OB-002 in Patients With Refractory Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
Sun Yat-sen University

Recruiting

Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer (REGOTORICOX)

Colorectal Cancer | Liver Metastases | MSS

China
Shanghai Yunying Medical Technology
The PLA Navy Anqing Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Non Small Cell Lung Cancer | Liver Cancer | Bronchial Cancer

China
The Affiliated Hospital of Qingdao University

Recruiting

XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation

Colon Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Colorectal Cancer
Liaoning Tumor Hospital & Institute

Not yet recruiting

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Northwestern University
National Cancer Institute (NCI)

Recruiting

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Colorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E Mutation

United States
NextCure, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer | Advanced or Metastatic Solid Tumors | Microsatellite Instability Low | Microsatellite Instability High | Microsatellite Stable | Head Neck Cancer

United States
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL845 in Adults With Solid Tumors

Melanoma | Colorectal Cancer | Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute

Not yet recruiting

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Recurrent Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma

United States
Jules Bordet Institute
Hoffmann-La Roche

Recruiting

A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients (COPERNIC)

Metastatic Colorectal Cancer | Unresectable Locally Advanced Colorectal Cancer | Candidate for Third-line or Subsequent Lines of Therapy

Belgium, France
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
LI XIN-XIANG

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis (Miracle-2)

Advanced Rectal Cancer | Distal Metastasis

China
National Cancer Institute (NCI)

Recruiting

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

United States
Innovative Cellular Therapeutics Inc.

Recruiting

GCC19CART for Patients With Metastatic Colorectal Cancer (CARAPIA-1)

Colorectal Cancer

United States
The Third Affiliated Hospital of Guangzhou Medical...
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer

China
Zhejiang University

Recruiting

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer

China
AIO-Studien-gGmbH
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (MEFOX)

Chemo-refractory Colorectal Carcinoma

Germany
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
University of California, Irvine
Natera, Inc.; Taiho Pharmaceutical Co., Ltd.

Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Colorectal Cancer | Colon Adenocarcinoma

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Melanoma | Neuroblastoma | Pancreatic Ductal Adenocarcinoma | Refractory Malignant Solid Neoplasm | Endometrial Carcinoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Non-Hodgkin Lymphoma | Recurrent Osteosarcoma | Refractory Ewing Sarcoma | Refractory... and other conditions

United States
IGM Biosciences, Inc.

Recruiting

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Sarcoma | Acute Myeloid Leukemia | Colorectal Cancer | Solid Tumor | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chondrosarcoma | Small Lymphocytic Lymphoma

United States, Korea, Republic of, France, Spain, Australia
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
KAEDI

Not yet recruiting

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Glioma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor

China
Aarhus University Hospital

Recruiting

Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases (SIRT)

Liver Metastasis Colon Cancer

Denmark
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumor | Liver Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (TOASTIT)

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Rhabdomyosarcoma | Refractory Rhabdomyosarcoma | Recurrent Colon Carcinoma | Recurrent Gastric Carcinoma | Recurrent Rectal Carcinoma | Refractory Sarcoma | Refractory Ovarian Carcinoma | Resectable... and other conditions

United States
Cliniques universitaires Saint-Luc- Université...

Recruiting

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI)

Colorectal Neoplasms, Malignant

Belgium
Arbeitsgemeinschaft medikamentoese Tumortherapie
Roche Pharma AG; AstraZeneca

Recruiting

Genomic Testing and Resulting Medical Decisions

Hematologic Neoplasms | Cancer Head Neck | Cancer, Breast | Cancer of Stomach | Cancer of Unknown Origin | Cancer Colorectal | Cancer, Lung | Cancer of Skin | Cancer of Esophagus | Cancer Refractory | Cancer, Bladder | Cancer, Uterus | Cancer Cervix | Cancer Liver | Cancer, Kidney

Austria
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Lynch Syndrome | Malignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Refractory Ependymoma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Refractory Diffuse Intrinsic Pontine Glioma | Recurrent Brain Neoplasm | Refractory Brain Neoplasm | Constitutional...

United States, Canada
University of Utah
National Cancer Institute (NCI)

Terminated

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer (APK Mutant)

Colorectal Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

BRAF V600 Colorectal Cancer

Belgium, Germany, Netherlands, Spain, Singapore, Australia, United Kingdom, Israel, Canada, United States

Search clinical trials for: Refractory colorectal cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations